Background: Chronic inflammatory demyelinating polyradiculoneuropathy is a rare acquired immune-mediated progressive or relapsing disorder causing peripheral neuropathic disease of duration more ...

A drug in advanced development for myasthenia gravis also showed promise as a treatment for primary Sjögren's syndrome, a ...

Jason Eagle was enjoying his time in the U.S. Navy when, about a decade ago, he realized something was off. He started to experience numbness in his leg, lost sensation in his hands and developed ...

The company’s initiation of a pivotal Phase 3 study for DNTH103 in treating chronic inflammatory demyelinating polyneuropathy (CIDP) is a significant step, with the potential to establish DNTH103 as a ...

Analyst Jonathan Chang from Leerink Partners reiterated a Buy rating on Zai Lab (ZLAB – Research Report) and keeping the price target at ...

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

慢性炎性脱髓鞘性多发性神经根神经病（CIDP）是一种罕见的由免疫介导的脱髓鞘性周围神经病1。CIDP患者会经历一系列的行动和感觉问题，包括从坐姿站起来困难、疼痛和疲劳、经常绊倒或摔倒。随着疾病进展，许多患者需依赖轮椅且无法工作，对患者造成严重的疾病负 ...

Equities researchers at HC Wainwright reduced their FY2024 EPS estimates for shares of Dianthus Therapeutics in a research ...

GSA Capital Partners LLP lifted its stake in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 66.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 24,634 shares of the ...

Spring House, Massachusetts Wednesday, November 13, 2024, 14:00 Hrs [IST] ...

Nipocalimab was well-tolerated over the six-month study period, with no major safety signals observed. The most common adverse events (AEs) were infections and infestations: 60.4% (n=32) in the ...